Work

Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.

Year: 2010

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2010.28.15_suppl.3089

Authors: A. Jimeno, R. S. Herbst, G. S. Falchook, W. A. Messersmith, S. Hecker, S. Peterson, D. F. Hausman, R. Kurzrock, S. G. Eckhardt, D. S. Hong

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2488175228

Cites:

Cited by: 32

Related to: 10